Updated recommendations move away from universal disqualification, emphasizing individualized risk assessment and shared decision making for athletes with heart conditions.
Systematic review shows that use of prescribed testosterone and SGLT-2 inhibitors is associated with erythrocytosis; but whether these drugs cause thrombosis remains unclear.